Gilead Sciences Inc.’s $11 billion bet on Kite Pharma Inc. is poised to pay off, with the approval Wednesday of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
Comment on The Wall Street Journal: Gilead shares rise after FDA approves cell-therapy drug Yescarta
MarketWatch.com - Top Stories, MarketWatch
Wed, 10/18/2017 - 3:20pm
Comment On This Story
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more